Thrombotic events in severe FXII deficiency in comparison with unaffected family members during a long observation period
- 20 Downloads
To investigate the occurrence of thrombotic events (myocardial infarction, deep vein thrombosis or ischemic stroke) in a group of 39 cases of severe FXII deficiency during a mean 22.5 years follow-up. All patients seen in Padua during the years 1968–2006 will the object of this investigation. FXII was less than or 1% of normal in all cases. Factor FXII activity in unaffected family members was 98% (range 90–140%). No patient or control had a thrombotic event in the past and none were on anticoagulant therapy. FV Leiden was present in one patient and in two controls whereas the G to A20210 prothrombin polymorphism was absent in both groups. There was one death among the patients (breast cancer) and one among the control (car accident). There were two thrombotic events (myocardial infarction and deep vein thrombosis) in the patient group and three (myocardial infarction and two deep vein thrombosis) in the control group. Heterozygous FV Leiden was present in the patient who had venous thrombosis, One of the two control subjects who developed venous thrombosis had heterozygous FV Leiden and was on oral contraception. The second control subject who developed venous thrombosis was on oral contraception and had varicose veins. No ischemic stroke was observed in the patients or controls. Periods of immobilization were 42 days and 38 days, respectively for FXII deficient patients and for the controls. Patients with severe FXII deficiency may present thrombotic events but these are similar to these presented by unaffected family members. As a consequence it may be stated that severe FXII deficiency does not appear to effect thrombotic events.
KeywordsThrombosis FXII deficiency Contact phase Coagulation
The study was supported in part (secretarial assistance) by the “Associazione Emofilia ed altre Coagulopatie delle tre Venezie”.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The study was performed according to the Helsinky Convention and its ethical standards.
- 3.Girolami A, de Marco L, Dal Bo Zanon R, Patrassi G, Cappellato MG (1985) Rarer quantitative and qualitative abnormalities of coagulation. Clin Haematol 14:385–411Google Scholar
- 7.Vergnes C, Lorient-Roudaut MF, Haissaguerre M, Roudaut R, Wicker P, Boisseau MR, Dallocchio M (1985) Thrombophlebitis and pulmonary embolism in congenital factor XII deficiency. Arch Mal Coeur Vaiss 78:440–443Google Scholar
- 14.Girolami A, Randi ML, Gavasso S, Lombardi AM, Spiezia F (2004) The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: a study of prevalence in 21 patients and review of the literature. J Thromb Thrombolysis 17:139–143, 2004CrossRefGoogle Scholar
- 19.Lombardi AM, Bortoletto E, Scarparo P, Scapin M, Santarossa L, Girolami A (2008) Genetic study in patients with factor XII deficiency: a report of three new mutations exon 13 (Q501STOP), exon 14 (P547L) and – 13C> T promoter region in three compound heterozygotes. Blood Coagul Fibrinolysis 19:639–643CrossRefGoogle Scholar
- 20.Girolami A, Scarpa R, Lazzarin M, Brunetti A (1968) Coagulopatia da deficienza di Fattore di Hageman (factor XII) prima ossrvazione in Italia.Riv. Crit Clin Med 58:265–278Google Scholar
- 23.Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698–3703Google Scholar
- 25.Girolami A, Ferrari S, Cosi E, Girolami B (2018) Cardiovascular diseases in congenital prekallikrein deficiency: comparison with other chance-associated morbidities. Blood Coagul Fibrinolysis 29:423–428Google Scholar
- 29.Saito H, Scott J, Movat HZ, Scialla SJ (1979) Molecular heterogeneity of hageman trait (factor XII deficiency): evidence that two of 49 subjects are cross-reacting material positive (CRM+). J Lab Clin Med 94:256–265Google Scholar